Does the media prefer RIGL or INVA?

In the previous week, Innoviva had 11 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for Innoviva and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.70 beat Innoviva's score of -0.52 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer RIGL or NVAX?

In the previous week, Novavax had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 7 mentions for Novavax and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.70 beat Novavax's score of 0.41 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to RIGL or ZBIO?

In the previous week, Zenas BioPharma had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for Rigel Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.90 beat Rigel Pharmaceuticals' score of 0.70 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RIGL or MNKD?

In the previous week, MannKind had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for MannKind and 2 mentions for Rigel Pharmaceuticals. MannKind's average media sentiment score of 1.17 beat Rigel Pharmaceuticals' score of 0.70 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rigel Pharmaceuticals (RIGL) Competitors

$36.55 +0.94 (+2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$37.07 +0.52 (+1.43%)

As of 07:55 PM Eastern

Compare

RIGL vs. BCRX, INVA, NVAX, ZBIO, and MNKD

Should you buy Rigel Pharmaceuticals stock or one of its competitors? MarketBeat compares Rigel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rigel Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Rigel Pharmaceuticals has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.30	$367.02M	$18.72	1.95
BioCryst Pharmaceuticals	$874.84M	2.90	$263.86M	-$1.78	N/A

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for BioCryst Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.70 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Positive
BioCryst Pharmaceuticals	Neutral

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 49.11%. BioCryst Pharmaceuticals has a consensus target price of $20.70, indicating a potential upside of 107.54%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Rigel Pharmaceuticals has a net margin of 121.50% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Rigel Pharmaceuticals' return on equity of 47.99% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

Rigel Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Innoviva?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Innoviva's net margin of 119.89%. Rigel Pharmaceuticals' return on equity of 47.99% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Innoviva	119.89%	33.33%	22.67%

Rigel Pharmaceuticals has higher earnings, but lower revenue than Innoviva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.30	$367.02M	$18.72	1.95
Innoviva	$411.33M	4.24	$271.17M	$6.01	3.93

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 49.11%. Innoviva has a consensus price target of $36.20, suggesting a potential upside of 53.13%. Given Innoviva's stronger consensus rating and higher probable upside, analysts clearly believe Innoviva is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Innoviva had 11 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for Innoviva and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.70 beat Innoviva's score of -0.52 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals and Innoviva tied by winning 8 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Novavax?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

Novavax has higher revenue and earnings than Rigel Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.30	$367.02M	$18.72	1.95
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A

Rigel Pharmaceuticals has a net margin of 121.50% compared to Novavax's net margin of -14.73%. Rigel Pharmaceuticals' return on equity of 47.99% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Novavax	-14.73%	-14.82%	1.23%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Novavax had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 7 mentions for Novavax and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.70 beat Novavax's score of 0.41 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals presently has a consensus price target of $54.50, indicating a potential upside of 49.11%. Novavax has a consensus price target of $13.00, indicating a potential upside of 46.15%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Rigel Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Rigel Pharmaceuticals beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Zenas BioPharma's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Zenas BioPharma	N/A	-99.99%	-58.06%

Rigel Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.30	$367.02M	$18.72	1.95
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

Rigel Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

In the previous week, Zenas BioPharma had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for Zenas BioPharma and 2 mentions for Rigel Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.90 beat Rigel Pharmaceuticals' score of 0.70 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 49.11%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 103.15%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Rigel Pharmaceuticals beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to MannKind?

Rigel Pharmaceuticals (NASDAQ:RIGL) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 121.50% compared to MannKind's net margin of -6.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
MannKind	-6.63%	-11.21%	-3.92%

Rigel Pharmaceuticals currently has a consensus target price of $54.50, suggesting a potential upside of 49.11%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 134.48%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rigel Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Rigel Pharmaceuticals has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.30	$367.02M	$18.72	1.95
MannKind	$348.97M	3.39	$5.86M	-$0.07	N/A

In the previous week, MannKind had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for MannKind and 2 mentions for Rigel Pharmaceuticals. MannKind's average media sentiment score of 1.17 beat Rigel Pharmaceuticals' score of 0.70 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$658.86M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	1.95	18.65	25.39	23.96
Price / Sales	2.30	341.96	530.17	107.90
Price / Cash	5.28	56.64	45.29	53.76
Price / Book	1.69	4.14	10.76	6.41
Net Income	$367.02M	$64.45M	$3.56B	$337.14M
7 Day Performance	9.53%	1.34%	1.37%	-0.48%
1 Month Performance	25.99%	0.95%	0.81%	0.49%
1 Year Performance	95.45%	24.33%	30.53%	28.16%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	3.2216 of 5 stars	$36.55 +2.6%	$54.50 +49.1%	+89.0%	$658.86M	$294.28M	1.95	160
BCRX BioCryst Pharmaceuticals	2.1941 of 5 stars	$9.14 +1.7%	$20.70 +126.5%	-6.1%	$2.28B	$874.84M	N/A	530	Options Volume High Trading Volume
INVA Innoviva	3.7639 of 5 stars	$22.67 +0.8%	$36.20 +59.7%	+13.2%	$1.66B	$411.33M	3.77	100	Trending News Analyst Forecast Analyst Revision
NVAX Novavax	1.8499 of 5 stars	$9.00 -1.4%	$13.00 +44.4%	+42.6%	$1.50B	$1.12B	N/A	1,990	News Coverage
ZBIO Zenas BioPharma	3.7756 of 5 stars	$20.80 +5.2%	$44.29 +112.9%	+113.3%	$1.25B	$10M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, INVA, NVAX, ZBIO, and MNKD

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, INVA, NVAX, ZBIO, and MNKD

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Which has better valuation and earnings, RIGL or BCRX?

Does the media prefer RIGL or BCRX?

Do institutionals and insiders have more ownership in RIGL or BCRX?

Which has more risk and volatility, RIGL or BCRX?

Do analysts recommend RIGL or BCRX?

Is RIGL or BCRX more profitable?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Is RIGL or INVA more profitable?

Which has better earnings and valuation, RIGL or INVA?

Do analysts prefer RIGL or INVA?

Does the media prefer RIGL or INVA?

Which has more risk and volatility, RIGL or INVA?

Do insiders and institutionals hold more shares of RIGL or INVA?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Which has more volatility and risk, RIGL or NVAX?

Which has better valuation & earnings, RIGL or NVAX?

Is RIGL or NVAX more profitable?

Do insiders and institutionals believe in RIGL or NVAX?

Does the media prefer RIGL or NVAX?

Do analysts prefer RIGL or NVAX?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Do insiders & institutionals hold more shares of RIGL or ZBIO?

Is RIGL or ZBIO more profitable?

Which has better valuation & earnings, RIGL or ZBIO?

Which has more risk & volatility, RIGL or ZBIO?

Does the media refer more to RIGL or ZBIO?

Do analysts prefer RIGL or ZBIO?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Do insiders and institutionals hold more shares of RIGL or MNKD?

Is RIGL or MNKD more profitable?

Do analysts prefer RIGL or MNKD?

Which has more risk and volatility, RIGL or MNKD?

Which has higher valuation and earnings, RIGL or MNKD?

Does the media refer more to RIGL or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools